TTR and amyloidosis: For example, onpattro (patisiran, Alnylam Pharmaceuticals) was the first siRNA drug, which was approved for clinical use to treat patients with hereditary transthyretin-mediated (hATTR) amyloidosis by the US Food and Drug Administration (FDA) in 2018 (Kristen et al., 2019).